Impact of VRC01 prophylaxis on HIV viral diversity and autologous antibody responses after infection
Official title: Assessing the longitudinal impact of VRC01 prophylaxis on viral populations and autologous antibody responses in breakthrough infections
Funded at Fred Hutchinson Cancer Center · NIH-11470486 · Data updated 2026-11-12
This project studies how giving a broadly neutralizing antibody (VRC01) before HIV infection may shape the virus and the body's own antibodies after infection in people who become HIV-positive anyway.
Quick facts
| Grant type | R21 grant |
|---|---|
| Study type | NIH-funded research |
| Funding institution | Fred Hutchinson Cancer Center NIH-funded |
| Lab location | 1 site (Seattle, United States) |
| Project start | August 18, 2026 |
| Project end | July 31, 2028 |
| Funding year | 2026 |
| Award (this year) | $278,333 |
| NIH project number | 1R21AI203620-01 |
| Project ID | NIH-11470486 on NIH RePORTER |
Who could benefit from this research
✓Could help
People who acquired HIV during prior VRC01 or placebo trial participation and have available longitudinal samples and clinical data.
✕Less likely to help
Individuals who were not participants in the AMP/ATI trials or lack available longitudinal samples may not directly benefit.
What this research studies
Researchers will analyze long-term data from prior HIV trials to see whether VRC01 exposure at infection changes viral diversity and the body's natural antibody responses during treatment interruption. They will compare those who received VRC01 with those given placebo to understand potential immunomodulatory effects. The work uses existing longitudinal samples and clinical data to identify patterns in rebound viruses and autologous antibody development. The goal is to inform future vaccines or antibody-based strategies by understanding how bnAbs influence early immune responses.
Why it matters
Potential benefit: If successful, the study could guide design of bnAb-based prevention or treatment approaches and improve understanding of how early antibody responses develop after bnAb exposure.
How similar studies have gone: Prior trials show that bnAbs can influence viral dynamics, but this analysis specifically examines immunologic and virologic outcomes in the context of VRC01 exposure at acquisition.
Where this research is happening
-
Fred Hutchinson Cancer Center
Seattle, United States Active
Researchers
- Principal investigator: Giorgi, Elena E. — Fred Hutchinson Cancer Center
- Study coordinator: Giorgi, Elena E.
About this research
- This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
- Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
- For full project details, budget, and progress reports, visit the official NIH RePORTER page.